Okazaki, Japan

Nobuo Harada

This inventor holds 3 USPTO granted patents. Top assignee: Banyu Pharmaceutical Co. Ltd. Active years: 1983-1988.


% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1983-1988

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Nobuo Harada: Innovator in Pharmaceutical Chemistry

Introduction

Nobuo Harada is a distinguished inventor based in Okazaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic applications.

Latest Patents

Harada holds a total of 3 patents. His latest patents include innovative processes for preparing dihydropyridine derivatives and compounds useful for treating hypertension. One notable patent involves a process for preparing a 2-carbamoyloxyalkyl-1,4-dihydropyridine derivative, which includes reacting specific acrylic acid derivatives with benzylidene compounds and aldehydes. Another patent focuses on an α-tocopheryl 5-substituted picolinate, which is produced by reacting substituted picolinic acids with α-tocopherol, offering potential benefits in hypertension treatment.

Career Highlights

Nobuo Harada is currently associated with Banyu Pharmaceutical Co. Ltd., where he continues to advance his research and development efforts. His work has been instrumental in creating pharmaceutical compositions that address critical health issues.

Collaborations

Harada has collaborated with notable colleagues, including Tetsuji Miyano and Kunio Suzuki, contributing to a dynamic research environment that fosters innovation.

Conclusion

Nobuo Harada's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in healthcare. His patents and ongoing research continue to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…